Gyre Therapeutics Inc
Research Gyre Therapeutics Inc (GYRE) on Bullrun: market cap USD 708.31M. Explore financials, valuation history, model signals, and stock context.
Key Metrics
- TickerGYRE
- ExchangeNASDAQ
- CountryUnited States
- SectorHealthcare
- IndustryBiotechnology
- CurrencyUSD
- Market capUSD 708.31M
- Financial periodQ2 2026
- RevenueUSD 29.11M
- Net income-USD 10.61M
- Free cash flow-USD 18.01M
- Gross margin92.4%
Valuation Snapshot
latest market cap is USD 708.31M.
Five-year financial history
| Year | Revenue | Net income | Free cash flow | Gross margin | Diluted EPS | Cash | Total debt | Equity |
|---|---|---|---|---|---|---|---|---|
| FY2025 | USD 116.59M | USD 9.88M | -USD 180.00K | 95.4% | 0.02 | USD 37.07M | USD 939.00K | USD 106.03M |
| FY2024 | USD 105.76M | USD 17.90M | -USD 5.96M | 96.3% | 0.05 | USD 11.81M | USD 1.60M | USD 63.32M |
| FY2023 | USD 113.45M | -USD 85.48M | USD 17.38M | 95.9% | -1.41 | USD 33.51M | USD 409.00K | -USD 15.83M |
| FY2022 | USD 102.29M | USD 4.31M | USD 5.69M | 95.3% | 0.03 | USD 25.18M | n/a | USD 42.52M |
Valuation history
| Year | Snapshot date | Market cap | P/E | Dividend yield | Annual dividend/share |
|---|---|---|---|---|---|
| 2026 | 2026-08-25 | USD 708.31M | n/a | n/a | n/a |
| 2025 | 2025-12-31 | USD 644.68M | 353.0 | n/a | n/a |
| 2024 | 2024-12-31 | USD 1.04B | 100.8 | n/a | n/a |
| 2023 | 2023-12-29 | USD 1.97B | n/a | 14.0% | 3.6 |
| 2022 | 2022-12-30 | n/a | 1.4 | 269.8% | 21.45 |
Dividend history
| Year | Dividends/share |
|---|---|
| FY2023 | 3.6 USD |
| FY2022 | 0.24 USD |
About Gyre Therapeutics Inc
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.
Related stock research
Other Healthcare stocks
Frequently asked questions
What is Gyre Therapeutics Inc's market cap?
Gyre Therapeutics Inc's market capitalization is USD 708.31M.
What does Gyre Therapeutics Inc do?
Gyre Therapeutics, Inc., a pharmaceutical company, engages in the development and commercialization of small-molecule, anti-inflammatory, and anti-fibrotic drugs targeting organ fibrosis. The company offers ETUARY (Pirfenidone), an anti-fibrotic drug approved for the treatment of idiopathic pulmonary fibrosis; and under Phase 3 trials for the treatment of pneumoconiosis.